NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
Clinical Trials
25 trialsNCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05064150 2025-12-18
NET-PRO
University of Iowa
Active not recruiting
NCT06889493 2025-12-17
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
University of Miami
Phase 1 Recruiting
NCT05262556 2025-08-07
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Case Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04464122 2025-04-03
REBORN
University of Roma La Sapienza
Recruiting
NCT06242119 2025-02-19
JPET2Clinic
Jagiellonian University
Recruiting
NCT02754297 2024-08-21
P-PRRT
CHU de Quebec-Universite Laval
Phase 2 Active not recruiting
NCT04524208 2024-08-13
CABONEN
University Medical Center Goettingen
Phase 2 Active not recruiting
NCT05396118 2024-05-14
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Phase 2 Enrolling by invitation
NCT06337760 2024-03-29
YOUNGSTER
European Institute of Oncology
Recruiting
NCT03834701 2024-02-13
RAPNEN
Catholic University of the Sacred Heart
Phase NA Completed
NCT05709171 2023-11-22
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Rigshospitalet, Denmark
Phase 2 Unknown
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT04525638 2022-08-02
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Phase 2 Unknown
NCT03352934 2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2 Completed
NCT05113355 2021-11-24
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04720391 2021-01-22
MONET
European Institute of Oncology
Unknown
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT01177007 2017-08-28
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Phase 2 Completed
NCT01396382 2016-03-29
68Ga
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT01886287 2015-01-12
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02038738 2014-01-17
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Phase 1/2 Unknown
NCT01203306 2010-09-16
XELBEVOCT
University of Turin, Italy
Phase 2 Unknown
NCT00953394 2009-08-06
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
University of Turin, Italy
Phase 2 Completed